Results about: cancer

Recent years have seen a paradigm shift in our understanding of gene activity and regulation. It is now clear that processing of primary transcripts as well as translational control open a myriad of opportunities for gene regulation, which are extensively used in virtually every human gene.

<p>Angel R Nebreda</p>

The Signalling and Cell Cycle Laboratory focuses on studying the basic mechanisms of cell regulation, especially regarding how external signals are interpreted by cells to modulate cell proliferation, differentiation and survival. Our research centers on two main subjects:


The recognition of many types of DNA lesions activates the cellular DNA damage response (DDR). The DDR orchestrates the appropriate cellular programs to maintain genome integrity after genotoxic stress.

A high resolution description of the structure and dynamics of proteins is a very useful tool to study the properties and the function of these important biomacromolecules and, most importantly, to understand how changes in sequence or environment can lead to disease.


Candidates with a strong interest in the microtubule cytoskeleton who would like to join our group should e-mail a cover letter with CV including contact information for references to

Our research focuses on three angles of peptide and protein chemistry: the design, synthesis and structure of bioactive molecules. From a structural perspective, we apply modern NMR techniques to study complex molecular recognition processes.

Identificats nous gens relacionats amb el risc de càncer

Investigadors del Centre de Regulació Genòmica (CRG) en col·laboració amb l'IRB Barcelona han desenvolupat un nou mètode per identificar sistemàticament a gens que contribueixen al risc de patir càncer hereditari.

L'estudi, publicat a Nature Communications, és un cas d'èxit sobre obertura, transparència i intercanvi de dades en ciència.

Un enzim podria tenir potencial terapèutic per al càncer de mama i una malaltia del cervell

Un nou estudi en col·laboració amb l'IRB Barcelona i liderat per la Universitat de Copenhaguen, revela que TLK2 mostra nivells més baixos d'activitat en discapacitat intel·lectual i que és possible inhibir-lo en el càncer de mama, on és hiperactiva.

L'estudi, per tant, suggereix que l'enzim pot ser un objectiu per a possibles teràpies.